These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34676266)

  • 21. Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer.
    Hernandez I; Gellad WF
    J Manag Care Spec Pharm; 2020 Feb; 26(2):154-159. PubMed ID: 32011961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
    Mansell K; Bhimji H; Eurich D; Mansell H
    BMC Health Serv Res; 2019 Nov; 19(1):827. PubMed ID: 31718624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
    Dempsey M; Mocarski M; Langer J; Hunt B
    J Med Econ; 2018 Nov; 21(11):1110-1118. PubMed ID: 30114954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The price paradox of biosimilar-like long-acting insulin.
    Mouslim MC; Rashidi ES; Levy JF; Socal MP; Trujillo AJ
    Am J Manag Care; 2022 Nov; 28(11):e405-e410. PubMed ID: 36374658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical benefits of switching to insulin degludec irrespective of previous basal insulin therapy in people with Type 1 or Type 2 diabetes: evidence from a European, multicentre, retrospective, non-interventional study (EU-TREAT).
    Knudsen ST; Lapolla A; Schultes B; Tentolouris N; Catarig AM; Wolden ML; Siegmund T
    Diabet Med; 2019 Jul; 36(7):868-877. PubMed ID: 31001865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of biosimilar insulins on the diabetes landscape.
    White J; Wagner A; Patel H
    J Manag Care Spec Pharm; 2022 Jan; 28(1):91-98. PubMed ID: 34726499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
    Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
    BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review.
    Caires de Souza AL; de Assis Acurcio F; Guerra Júnior AA; Rezende Macedo do Nascimento RC; Godman B; Diniz LM
    Appl Health Econ Health Policy; 2014 Feb; 12(1):19-32. PubMed ID: 24385261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
    Warren E; Weatherley-Jones E; Chilcott J; Beverley C
    Health Technol Assess; 2004 Nov; 8(45):iii, 1-57. PubMed ID: 15525480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes.
    Cheng H; Wan X; Ma J; Wu B
    Clin Ther; 2019 Mar; 41(3):445-455.e4. PubMed ID: 30713016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The advent of biosimilars for the treatment of diabetes: current status and future directions.
    Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP
    Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The biosimilar insulin landscape: current developments.
    Lavalle-González FJ; Khatami H
    Postgrad Med; 2014 Oct; 126(6):81-92. PubMed ID: 25414937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Production costs and potential prices for biosimilars of human insulin and insulin analogues.
    Gotham D; Barber MJ; Hill A
    BMJ Glob Health; 2018; 3(5):e000850. PubMed ID: 30271626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial.
    Evans M; Moes RGJ; Pedersen KS; Gundgaard J; Pieber TR
    Adv Ther; 2020 May; 37(5):2413-2426. PubMed ID: 32306247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
    Pollock RF; Heller S; Pieber TR; Woo V; Gundgaard J; Hallén N; Luckevich M; Tutkunkardas D; Zinman B;
    Diabetes Obes Metab; 2019 Jul; 21(7):1706-1714. PubMed ID: 30924579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilar insulins are coming: what they are, what you need to know.
    Edelman S; Polonsky WH; Parkin CG
    Curr Med Res Opin; 2014 Nov; 30(11):2217-22. PubMed ID: 25105307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK.
    Idris I; Gordon J; Tilling C; Vora J
    J Med Econ; 2015 Apr; 18(4):273-82. PubMed ID: 25422990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.
    Saunders H; Pham B; Loong D; Mishra S; Ashoor HM; Antony J; Darvesh N; Bains SK; Jamieson M; Plett D; Trivedi S; Yu CH; Straus SE; Tricco AC; Isaranuwatchai W
    Value Health; 2022 Jul; 25(7):1235-1252. PubMed ID: 35341688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
    Dempsey M; Mocarski M; Langer J; Hunt B
    Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.
    Mezquita-Raya P; Darbà J; Ascanio M; Ramírez de Arellano A
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):587-595. PubMed ID: 28649881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.